(2016). High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner.
Chicago Style (17th ed.) CitationHigh Dose CD11c-driven IL15 Is Sufficient to Drive NK Cell Maturation and Anti-tumor Activity in a Trans-presentation Independent Manner. 2016.
MLA (8th ed.) CitationHigh Dose CD11c-driven IL15 Is Sufficient to Drive NK Cell Maturation and Anti-tumor Activity in a Trans-presentation Independent Manner. 2016.
Warning: These citations may not always be 100% accurate.